Application segmentation in the Spirometry Software market isolates end‑use contexts that drive revenue allocation. The dominant clinical diagnosis segment, representing roughly 48 % of total sales, supplies software for routine outpatient and inpatient lung‑function assessment, where compliance with ATS/ERS standards mandates frequent updates, thus inflating licensing and support fees. Pulmonary function testing labs, accounting for about 27 % of the market, require high‑throughput, batch‑processing capabilities and integrate with laboratory information systems, generating higher per‑unit pricing. Research & development applications, contributing near 12 %, focus on data‑capture granularity and custom analytics for clinical trials, attracting premium subscription models. Telehealth monitoring occupies the remaining 13 %, a segment whose growth is propelled by reimbursement reforms. Impact of each application is measured by unit license fees and ancillary services such as training, maintenance, and data‑storage subscriptions, amplifying the segment’s share of market revenue. Reimbursement pathways for spirometry are expected to shift the telehealth proportion upward, while regulatory requirements for diagnostic accuracy sustain pricing of clinical‑diagnosis solutions. Collectively, these application categories define the overall Spirometry Software segmentation, and their relative weightings are reflected in the accompanying pie‑chart.